Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

BLASTOID-DISCOVERY Human blastoids: a drug discovery platform for women’s reproductive health

Coordinator
Institut Fuer Molekulare Biotechnologie GmbH, Austria
Runs
1 November 2023 to 30 April 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101082147

What the project is doing

In the project's own words, from its summary on CORDIS.

The first weeks of human pregnancy are crucial as early abnormalities or insults result in infertility. Therapeutics acting at the onset of embryonic development would offer huge opportunities to improve public health through effective family planning and to reduce an ongoing global fertility decrease with profound economic, social, environmental, and geopolitical consequences. Unfortunately, a drug development program on human embryos is unfeasible due to the inaccessibility and scarcity of embryos, and to ethical issues associated with them.

As a result, the attrition rate of drugs for reproductive health is high for all major In Vitro Fertilization (IVF) and pharmaceutical companies. Recently, an alternative approach arose from stem cells self-organizing into structures closely resembling pre-implantation embryos (blastocysts), which we termed blastoids. Because stem cells can be largely multiplied, this embryo model provides a scalable and ethical alternative amenable to drug screens, thus opening numerous possibilities for therapeutic breakthroughs.

Here, I propose to use human blastoids to discover molecules for women’s reproductive health. Blastoids offer a unique opportunity to establish a drug discovery program for early pregnancy and an alternative to the use of animal and human embryos. As such, this path has the potential to decrease the cost of drug development and to increase the rate of approved drugs for reproductive health. The aim of BLASTOID-DISCOVERY is to investigate the commercial feasibility of using blastoids as a new and highly cost-effective tool in the discovery of therapeutics for reproductive health.

Topics

Who is involved

OrganisationCityCountryRole
Institut Fuer Molekulare Biotechnologie GmbHWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI